What is the recommended concentration of polymyxin B (antibiotic) in eye drops, 10000 units/mL or 1 mg/mL?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 28, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Polymyxin B Ophthalmic Concentration: Both Are Equivalent

The recommended concentration is 10,000 units/mL, which is exactly equivalent to 1 mg/mL, since 1 mg of polymyxin B sulfate equals 10,000 units. 1, 2

Understanding the Conversion

  • The critical conversion factor is: 1 mg polymyxin B sulfate = 10,000 units 1, 2
  • This means that 10,000 units/mL and 1 mg/mL represent the identical concentration—they are simply different ways of expressing the same amount 1
  • This conversion is specific to polymyxin B and differs significantly from colistin (polymyxin E), where 1 million IU = approximately 80 mg of colistimethate sodium 1, 2

FDA-Approved Ophthalmic Formulation

  • The FDA-approved polymyxin B ophthalmic solution contains polymyxin B sulfate at 10,000 units/mL (equivalent to 1 mg/mL) combined with trimethoprim 1 mg/mL 3
  • This formulation is preserved with benzalkonium chloride 0.04 mg/mL and has a pH of 4.0-6.2 3
  • The osmolality is 270-310 mOsm/kg, making it suitable for topical ocular use 3

Clinical Context

  • When prescribing or preparing polymyxin B eye drops, either notation (10,000 units/mL or 1 mg/mL) is correct and refers to the same concentration 3
  • The common pitfall is confusing polymyxin B unit conversions with colistin conversions—these are completely different antibiotics with different conversion factors 1, 2
  • For ophthalmic use, polymyxin B demonstrates bactericidal activity against gram-negative organisms, particularly Pseudomonas aeruginosa, E. coli, Klebsiella pneumoniae, and Haemophilus influenzae 3

References

Guideline

Polymyxin B Dosing and Indications for Multidrug-Resistant Gram-Negative Bacteria

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Polymyxin B Dosing Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.